Equities Analysts Set Expectations for BHC Q3 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research reduced their Q3 2025 EPS estimates for shares of Bausch Health Companies in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.06 per share for the quarter, down from their previous forecast of $1.15. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2026 earnings at $0.97 EPS, Q3 2026 earnings at $1.13 EPS, Q4 2026 earnings at $1.12 EPS and Q1 2027 earnings at $1.11 EPS.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion.

A number of other equities analysts have also weighed in on BHC. Royal Bank of Canada boosted their price objective on Bausch Health Companies from $8.50 to $10.00 and gave the stock a “sector perform” rating in a research note on Friday, May 2nd. Wall Street Zen cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $4.46 on Friday. Bausch Health Companies has a one year low of $3.96 and a one year high of $9.85. The stock has a market cap of $1.61 billion, a PE ratio of -37.12, a P/E/G ratio of 0.37 and a beta of 0.34. The stock has a 50 day moving average price of $5.31 and a 200 day moving average price of $6.82.

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. grew its holdings in shares of Bausch Health Companies by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company’s stock worth $27,000 after purchasing an additional 3,001 shares during the period. Cary Street Partners Financial LLC acquired a new position in Bausch Health Companies in the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd purchased a new position in Bausch Health Companies during the first quarter worth about $27,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Bausch Health Companies during the fourth quarter valued at about $56,000. Finally, Wealthquest Corp acquired a new stake in shares of Bausch Health Companies during the first quarter valued at about $58,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.